Terms: = Germ cell tumor AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1
1439 results:
1. Targeting nras via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.
Pucci P; Lee LC; Han M; Matthews JD; Jahangiri L; Schlederer M; Manners E; Sorby-Adams A; Kaggie J; Trigg RM; Steel C; Hare L; James ER; Prokoph N; Ducray SP; Merkel O; Rifatbegovic F; Luo J; Taschner-Mandl S; Kenner L; Burke GAA; Turner SD
Nat Commun; 2024 Apr; 15(1):3422. PubMed ID: 38653965
[TBL] [Abstract] [Full Text] [Related]
2. Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.
Sukniam K; Manaise HK; Popp K; Popp R; Gabriel E
Cells; 2024 Mar; 13(6):. PubMed ID: 38534309
[TBL] [Abstract] [Full Text] [Related]
3. Evolution of Testicular germ cell tumors in the Molecular Era With Histogenetic Implications.
Kilic I; Acosta AM; Idrees MT
Adv Anat Pathol; 2024 May; 31(3):206-214. PubMed ID: 38525515
[TBL] [Abstract] [Full Text] [Related]
4. Melanoma on congenital melanocytic nevi.
Alos L; Carrasco A; Teixidó C; Szumera-Ciećkiewicz A; Vicente A; Massi D; Carrera C
Pathol Res Pract; 2024 Apr; 256():155262. PubMed ID: 38518732
[TBL] [Abstract] [Full Text] [Related]
5. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced nras-mutant melanoma.
Wei X; Zou Z; Zhang W; Fang M; Zhang X; Luo Z; Chen J; Huang G; Zhang P; Cheng Y; Liu J; Liu J; Zhang J; Wu D; Chen Y; Ma X; Pan H; Jiang R; Liu X; Ren X; Tian H; Jia Z; Guo J; Si L
Eur J Cancer; 2024 May; 202():114008. PubMed ID: 38479118
[TBL] [Abstract] [Full Text] [Related]
6. Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances.
Kim HJ; Kim YH
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474231
[TBL] [Abstract] [Full Text] [Related]
7. Restrospective reappraisal of the prognostic classification of spitzoid melanocytic neoplasms after BRAF and nras mutation characterisation: a single institution experience.
Moysset I; Castrejon N; Garcia-Herrera A; Castillo P; Marginet M; Teixido C; Podlipnik S; Albero-Gonzalez R; Montironi C; Navarro J; Rovira C; Puig S; Carrera C; Alos L
Histopathology; 2024 Jun; 84(7):1154-1166. PubMed ID: 38409889
[TBL] [Abstract] [Full Text] [Related]
8. Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120's Anti-tumor Effects in Equine, Canine, and Human Malignant Melanoma cell Lines.
Gao Y; Packeiser EM; Wendt S; Sekora A; Cavalleri JV; Pratscher B; Alammar M; Hühns M; Brenig B; Junghanss C; Nolte I; Murua Escobar H
Genes (Basel); 2024 Feb; 15(2):. PubMed ID: 38397192
[TBL] [Abstract] [Full Text] [Related]
9. Assessment of RAS-RAF-MAPK Pathway Mutation Status in Healthy Skin, Benign Nevi, and Cutaneous Melanomas: Pilot Study Using Droplet Digital PCR.
Dobre EG; Nichita L; Popp C; Zurac S; Neagu M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396984
[TBL] [Abstract] [Full Text] [Related]
10. The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in nras/MAPK-driven melanoma.
Feichtenschlager V; Chen L; Zheng YJ; Ho W; Sanlorenzo M; Vujic I; Fewings E; Lee A; Chen C; Callanan C; Lin K; Qu T; Hohlova D; Vujic M; Hwang Y; Lai K; Chen S; Nguyen T; Muñoz DP; Kohwi Y; Posch C; Daud A; Rappersberger K; Kohwi-Shigematsu T; Coppé JP; Ortiz-Urda S
Mol Cancer; 2024 Feb; 23(1):40. PubMed ID: 38383439
[TBL] [Abstract] [Full Text] [Related]
11. HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker.
Amrane K; Le Meur C; Besse B; Hemon P; Le Noac'h P; Pradier O; Berthou C; Abgral R; Uguen A
Front Immunol; 2023; 14():1285895. PubMed ID: 38299143
[TBL] [Abstract] [Full Text] [Related]
12. nras Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma tumor Growth.
Cai C; Tu J; Najarro J; Zhang R; Fan H; Zhang FQ; Li J; Xie Z; Su R; Dong L; Arellano N; Ciboddo M; Elf SE; Gao X; Chen J; Wu R
Mol Cancer Res; 2024 Apr; 22(4):386-401. PubMed ID: 38294692
[TBL] [Abstract] [Full Text] [Related]
13. Primary Diffuse Leptomeningeal Melanomatosis in a Child with Extracranial Metastasis: Case Report.
Shahab SW; Patil P; Fangusaro JR; Patteson B; Goldman-Yassen A; Eaton BR; Boydston W; Schniederjan M; Aguilera D
Curr Oncol; 2024 Jan; 31(1):579-587. PubMed ID: 38275834
[TBL] [Abstract] [Full Text] [Related]
14. Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy.
Meraz-Torres F; Niessner H; Plöger S; Riel S; Schörg B; Casadei N; Kneilling M; Schaller M; Flatz L; Macek B; Eigentler T; Rieß O; Garbe C; Amaral T; Sinnberg T
J Exp Clin Cancer Res; 2024 Jan; 43(1):30. PubMed ID: 38263136
[TBL] [Abstract] [Full Text] [Related]
15. Cooperative function of oncogenic MAPK signaling and the loss of Pten for melanoma migration through the formation of lamellipodia.
Yasuta Y; Kaminaka R; Nagai S; Mouri S; Ishida K; Tanaka A; Zhou Y; Sakurai H; Yokoyama S
Sci Rep; 2024 Jan; 14(1):1525. PubMed ID: 38233537
[TBL] [Abstract] [Full Text] [Related]
16. The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase Inhibition.
Chen YK; Kanouni T; Arnold LD; Cox JM; Gardiner E; Grandinetti K; Jiang P; Kaldor SW; Lee C; Li C; Martin ES; Miller N; Murphy EA; Timple N; Tyhonas JS; Vassar A; Wang TS; Williams R; Yuan D; Kania RS
J Med Chem; 2024 Feb; 67(3):1747-1757. PubMed ID: 38230963
[TBL] [Abstract] [Full Text] [Related]
17. Melanoma of the central nervous system based on neurocutaneous melanocytosis in childhood: A rare but fatal condition.
Abele M; Forchhammer S; Eigentler TK; Popescu A; Maschke L; Lohse J; Lehrnbecher T; Behnisch W; Groll AH; Jakob M; Bernbeck B; Brecht IB; Schneider DT
Pediatr Blood Cancer; 2024 Apr; 71(4):e30859. PubMed ID: 38225622
[TBL] [Abstract] [Full Text] [Related]
18. Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model.
Iorgulescu JB; Ruthen N; Ahn R; Panagioti E; Gokhale PC; Neagu M; Speranza MC; Eschle BK; Soroko KM; Piranlioglu R; Datta M; Krishnan S; Yates KB; Baker GJ; Jain RK; Suvà ML; Neuberg D; White FM; Chiocca EA; Freeman GJ; Sharpe AH; Wu CJ; Reardon DA
Front Immunol; 2023; 14():1297932. PubMed ID: 38213329
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres.
Pallocca M; Molineris I; Berrino E; Marcozzi B; Betti M; Levati L; D'Atri S; Menin C; Madonna G; Ghiorzo P; Bulgarelli J; Ferraresi V; Venesio T; Rodolfo M; Rivoltini L; Lanfrancone L; Ascierto PA; Mazzarella L; Pelicci PG; De Maria R; Ciliberto G; Medico E; Russo G
J Transl Med; 2024 Jan; 22(1):29. PubMed ID: 38184610
[TBL] [Abstract] [Full Text] [Related]
20. Low incidence of BRAF and nras mutations in a population with a high incidence of melanoma.
Neville G; Marzario B; Shilling D; Hand CK; Heffron C
Virchows Arch; 2024 Mar; 484(3):475-479. PubMed ID: 38183457
[TBL] [Abstract] [Full Text] [Related]
[Next]
